0.35Open0.35Pre Close0 Volume4 Open Interest110.00Strike Price0.00Turnover194.54%IV53.20%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type-0.0108Delta0.0003Gamma669.37Leverage Ratio-0.0900Theta-0.0009Rho-7.26Eff Leverage0.0123Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet